1. Home
  2. SCHL vs AUTL Comparison

SCHL vs AUTL Comparison

Compare SCHL & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Scholastic Corporation

SCHL

Scholastic Corporation

HOLD

Current Price

$34.91

Market Cap

672.6M

ML Signal

HOLD

Logo Autolus Therapeutics plc

AUTL

Autolus Therapeutics plc

N/A

Current Price

$1.90

Market Cap

596.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SCHL
AUTL
Founded
1920
2014
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Books
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
672.6M
596.2M
IPO Year
1995
2025

Fundamental Metrics

Financial Performance
Metric
SCHL
AUTL
Price
$34.91
$1.90
Analyst Decision
Hold
Strong Buy
Analyst Count
1
4
Target Price
$40.00
$8.50
AVG Volume (30 Days)
258.0K
2.2M
Earning Date
03-19-2026
05-14-2026
Dividend Yield
1.99%
N/A
EPS Growth
3442.86
N/A
EPS
2.34
N/A
Revenue
$1,487,100,000.00
$10,120,000.00
Revenue This Year
$1.88
$80.32
Revenue Next Year
$4.05
$53.96
P/E Ratio
$14.96
N/A
Revenue Growth
N/A
496.00
52 Week Low
$22.69
$1.18
52 Week High
$48.07
$2.58

Technical Indicators

Market Signals
Indicator
SCHL
AUTL
Relative Strength Index (RSI) 28.93 41.61
Support Level $32.81 $1.37
Resistance Level $36.00 $2.07
Average True Range (ATR) 1.53 0.10
MACD -0.29 -0.08
Stochastic Oscillator 11.37 15.00

Price Performance

Historical Comparison
SCHL
AUTL

About SCHL Scholastic Corporation

Scholastic Corp is a publisher and distributor of children's books, a provider of print and digital instructional materials for grades pre-kindergarten (pre-K) to grade 12 and a producer of entertaining literary and educational children's media. The company creates quality print, digital and audio books, learning materials and programs, classroom magazines and other products that, in combination, offer children, families and educators engaging and comprehensive solutions to support children's learning and reading both at home and at school. It categorizes its businesses into four reportable segments: Children's Book Publishing and Distribution; Education; Entertainment; and International. It derives the majority of revenue from Children's Book Publishing and Distribution segment.

About AUTL Autolus Therapeutics plc

Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.

Share on Social Networks: